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Response to Letter to the Editor re: Outcome of
Endovenous Laser Therapy for Saphenous Reflux and
Varicose Veins: Medium - Term Results Assessed by
Ultrasound
Drs. Ghosh and Baguneid agree with our conclusion that ‘‘It
may well be that success rates will improve with increasing
power .’’, although multivariate analysis showed no rela-
tion between power and outcome. However, the references
quoted provide little assistance. Mordon et al.1 studied
a mechanical model and reported that ‘‘for a 3 mm vein
diameter. for 10 W and 2 mm/s pullback speed.
a minimum of 100 J/cm.,’’ and that ‘‘for a 5 mm vein
diameter. for 15 W and 2 mm/s pullback speed.
a minimum of 150 J/cm.’’ is required to damage the vessel
wall. Theivacumar et al.2 reported median energy density of
48 J cm1 in limbs with complete occlusion and 37 J cm1 in
those with partial occlusion; it is unlikely that these would
differ significantly from the median 44 J cm1 reported in
our study. The techniques in both references differed from
ours and, therefore, comparisons cannot be made.
Prince et al. reported no difference for early re-canal-
isation rates for energy ranging from <60 J cm1 to
>100 J cm1,3 whereas Vuylsteke et al. reported a signifi-
cantly higher mean fluence for veins that remained occluded
than for those that failed early.4 Proebsle et al. reported that
low fluence increased risk for early failure,5 and that
patients treated with 30 W had better medium-term results
than for those treated with 15 W.6 These studies also used
techniques other than those used in our report.
The effect of laser energy is dependent on wavelength,
power, probe-withdrawal rate and whether energy is contin-
uous or pulsed. Commercial systems use wavelengths from
810 nm to 1500 nm. Planck’s formula indicates that energy is
proportional to frequency so that higher wavelengths require
more exposure time. Published reports use either continuous
orpulsedpowerat various levels to15 W.WeagreewithGhosh
and Baguneid that determining best protocols to provide
highest long-term occlusion rates with least patient discom-
fort requires randomisation for these variables with long-term
surveillance, and we thank them for stimulating discussions.
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Plaque Biology, Realizing the Clinical Potential
In their carotid masterclass, Loftus and Thompson address
the question if plaque biology is interesting science or
a pharmacological treasure trove, concluding that it is more
of the former than the latter.1
Recent data suggest that carotid plaque phenotype in fact
may be the major independent determinant of the degree of
benefit of carotid endarterectomy. Carotid plaque composi-
tion is closely related to clinical presentation,2,3 gender,4 age5
andtime intervalbetweenmost recent ischemic symptomsand
CEA.6,7 We think it is no co-incidence that these clinical char-
acteristics are also the major determinants of CEA benefit,8
because theyare all associated with plaque composition that is
thought to portray an increased stroke risk if untreated, i.e. an
inflamed plaque with a large lipid pool and a thin fibrous cap.9
There is strong accumulating evidence from descriptive
and now also longitudinal studies that specific plaque
composition is related with adverse outcome following CEA.
Recently the Athero-Express study reported that plaque
composition is a strong independent predictor of restenosis
following CEA.10
Considering these recent data, we feel the question
should not be if plaque composition is relevant, but rather
how soon we will be able to include measurements of
plaque composition in decision making in clinical practice.DOI of original article: 10.1016/j.ejvs.2008.06.002.
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